News | April 01, 2022
Sumitomo Chemical to build new API and intermediates plant in Japan
The plant is scheduled to come on stream in September 2024
The plant is scheduled to come on stream in September 2024
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Subscribe To Our Newsletter & Stay Updated
